GlobalData
ReportStore
 

Home
Industry Reports
Pharmaceuticals and Healthcare

 
Single User License: 
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Buy Now Add to Cart
$2,000.00
Site License: 
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Buy Now Add to Cart
$4,000.00
Global License: 
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Buy Now Add to Cart
$6,000.00
Tab
Description
Table of Contents
List of Figures
List of Tables
Request Sample Pages
Send To Friend
Inquire Before Buying
 

Major Depressive Disorder (MDD) - Drug Pipeline Analysis and Market Forecasts to 2015

Published: Dec-2009   Report Code: GDHCPRT002
Report Format: Electronic PDF
 
GlobalData, the industry analysis specialist’s new report, “Major Depressive Disorder – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global major depression market. The report identifies the key trends shaping and driving the global major depressive disorder market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global major depressive disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

  • The scope of the report includes:
  • Annualized global major depressive disorder market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
  • Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin and Norepinephrine reuptake inhibitor (SNRI), Dopamine Antagonists, Neurokinin (NK) antagonists, NMDA, Triple reuptake inhibitor (serotonin, norepinephrine and dopamine) and Monoamine Oxidase (MAO)-A inhibitors.
  • Analysis of the current and future market competition in the global major depressive disorder market. Key market players covered are GlaxoSmithKline, AstraZeneca, H.Lundbeck, Pfizer, and Eli Lilly.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with major depressive disorder.

Reasons to Buy

  • The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global major depressive disorder market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global major depressive disorder market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global major depressive disorder market landscape? – Identify, understand and capitalize.